Results 161 to 170 of about 1,991 (194)
Some of the next articles are maybe not open access.
Mavacamten—A Targeted Therapy for Hypertrophic Cardiomyopathy
Journal of Cardiovascular Pharmacology, 2023Abstract: The pathophysiology of hypertrophic cardiomyopathy is primarily comprised of dynamic left ventricular outflow tract obstruction, mitral regurgitation, and diastolic dysfunction. Symptoms such as dyspnea, angina, or syncope can occur because of left ventricular (LV) hypertrophy and reduced LV cavity size.
Ashley, Schenk, Nathan, Fields
openaire +2 more sources
New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2023Abstract: Obstructive hypertrophic cardiomyopathy results from asymmetric septal hypertrophy, which eventually obstructs the outflow of the left ventricle. Obstructive hypertrophic cardiomyopathy is linked to mutations in genes that encode for sarcomere proteins, including actin, β-myosin heavy chain, titin, and troponin.
Rami A. Al-Horani, Ma’Lik Woodland
openaire +2 more sources
Canadian Journal of Health Technologies, 2023
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy
Annals of Internal Medicine, 2019Mavacamten, an orally administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic cardiomyopathy (oHCM).To characterize the effect of mavacamten on left ventricular outflow tract (LVOT) gradient.Open-label, nonrandomized, phase 2 trial. (ClinicalTrials.gov: NCT02842242).5 academic
Stephen B, Heitner +9 more
openaire +2 more sources
Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy
Clinical TherapeuticsHypertrophic cardiomyopathy (HCM) is an under-recognized genetic cardiac disorder affecting the muscles and contractility of the heart, which in turn can result in heart failure symptoms, arrhythmia, and sudden cardiac death. Previously, pharmacotherapy options for HCM were not disease-specific, often poorly tolerated, and overall inadequate for ...
J. Chase Cole +2 more
openaire +2 more sources
Mavacamten for obstructive hypertrophic cardiomyopathy
PrescriberMavacamten (Camzyos) is a cardiac myosin inhibitor indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. This article discusses its efficacy, adverse effects and place in therapy.
openaire +1 more source
Mavacamten for hypertrophic cardiomyopathy: effectiveness and value.
Journal of managed care & specialty pharmacy, 2022DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions.
Molly, Beinfeld +6 more
openaire +1 more source
Evaluation of mavacamten in patients with hypertrophic cardiomyopathy
Journal of Cardiovascular MedicineAims We aimed to comprehensively assess the safety and efficacy of mavacamten in hypertrophic cardiomyopathy (HCM) patients. Methods A systematic review and meta-analysis was conducted, and efficacy [changes in postexercise left ventricular outflow tract (LVOT) gradient, left ...
Hui-Ling, Liao, Yi, Liang, Bo, Liang
openaire +2 more sources
Mavacamten: treatment aspirations in hypertrophic cardiomyopathy
The Lancet, 2020Michael, Papadakis +2 more
openaire +2 more sources